Clinical Quiz: Biologics for CRSwNP

Credit: HCPLive

For many patients with chronic rhinosinusitis with nasal polyposis (CRSwNP), standard therapies such as intranasal corticosteroids and sinus surgery provide symptomatic relief. However, an estimated 30–40% of patients experience recurrent or refractory disease, necessitating advanced treatment options. The emergence of biologic therapies has transformed the management of severe CRSwNP, offering targeted treatment for patients with type 2 inflammation.

The GRADE guidelines provide evidence-based recommendations on the use of biologics, including monoclonal antibodies targeting IL-4, IL-5, and IL-13 pathways, which play key roles in eosinophilic inflammation. Clinical trials have demonstrated that biologics such as dupilumab, omalizumab, and mepolizumab can significantly reduce polyp burden, improve nasal obstruction, and restore olfaction in patients with uncontrolled CRSwNP. Despite their efficacy, questions remain regarding patient selection, long-term safety, and the cost-effectiveness of these therapies compared to traditional treatment modalities.

This quiz will assess your understanding of biologic therapy in CRSwNP, exploring guideline recommendations, patient eligibility criteria, and real-world clinical applications. Are you up to date on the latest advances in precision medicine for CRSwNP? Take the quiz to find out.